ondansetron (Q410011)

ondansetron (English)

19 November 2016

canonical SMILES

CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C

1 reference

ondansetron (English)

19 November 2016

defined daily dose

16 milligram

oral administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=A04AA01

16 milligram

parenteral route of administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=A04AA01

16 milligram

rectal route of administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=A04AA01

1 reference

14 February 2018

1 reference

14 February 2018

0 references

World Health Organisation international non-proprietary name

ondansetron (English)

2 references

Ondansetron (English)

medical condition treated

19 January 2016

published in

Recommended INN: List 29

publication date

1989

1 reference

Drug Indications Extracted from FAERS

13 December 2016

1 reference

significant drug interaction

2 October 2018

(RS)-methadone

1 reference

High-priority drug–drug interactions for use in electronic health records

amiodarone

1 reference

High-priority drug–drug interactions for use in electronic health records

anagrelide

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

astemizole

1 reference

High-priority drug–drug interactions for use in electronic health records

azithromycin

1 reference

High-priority drug–drug interactions for use in electronic health records

bepridil

1 reference

High-priority drug–drug interactions for use in electronic health records

chloroquine

1 reference

High-priority drug–drug interactions for use in electronic health records

chlorpromazine

1 reference

High-priority drug–drug interactions for use in electronic health records

cisapride

1 reference

High-priority drug–drug interactions for use in electronic health records

(RS)-citalopram

1 reference

High-priority drug–drug interactions for use in electronic health records

clarithromycin

1 reference

High-priority drug–drug interactions for use in electronic health records

cocaine

1 reference

High-priority drug–drug interactions for use in electronic health records

disopyramide

1 reference

High-priority drug–drug interactions for use in electronic health records

dofetilide

1 reference

High-priority drug–drug interactions for use in electronic health records

domperidone

1 reference

High-priority drug–drug interactions for use in electronic health records

dronedarone

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

erythromycin

1 reference

High-priority drug–drug interactions for use in electronic health records

escitalopram

1 reference

High-priority drug–drug interactions for use in electronic health records

flecainide

1 reference

High-priority drug–drug interactions for use in electronic health records

halofantrine

1 reference

High-priority drug–drug interactions for use in electronic health records

haloperidol

1 reference

High-priority drug–drug interactions for use in electronic health records

ibutilide

1 reference

High-priority drug–drug interactions for use in electronic health records

mesoridazine

1 reference

High-priority drug–drug interactions for use in electronic health records

moxifloxacin

1 reference

High-priority drug–drug interactions for use in electronic health records

pentamidine

1 reference

High-priority drug–drug interactions for use in electronic health records

pimozide

1 reference

High-priority drug–drug interactions for use in electronic health records

probucol

1 reference

High-priority drug–drug interactions for use in electronic health records

procainamide

1 reference

High-priority drug–drug interactions for use in electronic health records

quinidine

1 reference

High-priority drug–drug interactions for use in electronic health records

sevoflurane

1 reference

High-priority drug–drug interactions for use in electronic health records

sotalol

1 reference

High-priority drug–drug interactions for use in electronic health records

sparfloxacin

1 reference

High-priority drug–drug interactions for use in electronic health records

(RS)-sulpiride

1 reference

High-priority drug–drug interactions for use in electronic health records

terfenadine

1 reference

High-priority drug–drug interactions for use in electronic health records

thioridazine

1 reference

High-priority drug–drug interactions for use in electronic health records

(RS)-methadone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

amiodarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

disopyramide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

erythromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

haloperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlorpromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

A reference set of clinically relevant adverse drug-drug interactions

moxifloxacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dronedarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

crizotinib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pimozide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

zuclopenthixol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vandetanib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-hydroxyzine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-sulpiride

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pentamidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

domperidone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

apomorphine

hypotension

1 reference

established

A reference set of clinically relevant adverse drug-drug interactions

(Z)-Toremifene

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sotalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

apomorphine

1 reference

established

A reference set of clinically relevant adverse drug-drug interactions

amiodarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cardiotoxicity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cardiotoxicity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(Z)-Toremifene

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sotalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-sulpiride

1 reference

A reference set of clinically relevant adverse drug-drug interactions

apomorphine

altered state of consciousness

1 reference

established

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

5-hydroxytryptamine receptor 3A

subject has role

antagonist

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

2290

Australian pregnancy category B1

17 August 2016

pregnancy category

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category B

1 reference

imported from Wikimedia project

1 reference

https://www.pfizer.com/products/product-list

mass

293.152812 dalton

1 reference

ondansetron (English)

3 October 2016

1 reference

15 March 2018

1 reference

15 March 2018

1 reference

15 March 2018

1 reference

15 March 2018

1 reference

National Library of Spain SpMaBN ID (BNE v1.0)

15 March 2018

0 references

0 references

0 references

Ondansetron

0 references

Identifiers

XX547677

0 references

InChI

InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3

1 reference

ondansetron (English)

19 November 2016

2 references

ondansetron (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

99614-02-5

2 references

https://commonchemistry.cas.org/detail?cas_rn=99614-02-5

ondansetron (English)

19 November 2016

6 April 2021

1 reference

Ondansetron (English)

19 November 2016

2 references

ondansetron (English)

19 November 2016

ChEBI ID

7773

mapping relation type

2 references

ONDANSETRON (English)

19 November 2016

International Chemical Identifier

InChI

InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3

1 reference

ONDANSETRON (English)

19 November 2016

2 references

inferred from InChIKey

splash10-006x-0790000000-39dfc83ad8c54c21d83d

1 reference

MassBank accession ID

SM852501

0 references

SPLASH

0 references

HSDB ID

8304

1 reference

Hazardous Substances Data Bank

28 October 2019

Ondansetron (English)

10 May 2021

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.110.918

27 December 2018

ECHA Substance Infocard ID

9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one (English)

quotation

CAS no.: 99614-02-5 (English)

100.110.918

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.110.918

27 December 2018

9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one (English)

quotation

CAS no.: 99614-02-5 (English)

1 reference

World Health Organisation international non-proprietary name numeric ID

Ondansetron (English)

publication date

17 November 2015

5965

1 reference

https://mednet-communities.net/inn/db/ViewINN.aspx?i=5965

Guide to Pharmacology Ligand ID

2290

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

2290

ondansetron (English)

19 November 2016

Ondansetron

0 references

0 references

D03.633.100.473.144.500

0 references

0 references

1 reference

ondansetron (English)

19 November 2016

DrugBank ID

DB00904

1 reference

Human Metabolome Database ID

HMDB0005035

2 references

based on heuristic

inferred from InChIKey

2 references

ondansetron (English)

19 November 2016

MedlinePlus drug identifier

a601209

oral administration

0 references

a606022

PatientsLikeMe treatment ID

intravenous injection

intramuscular injection

0 references

0 references

1 reference

ondansetron (English)

19 November 2016

0 references

1 reference

1 reference

Ondansetron (English)

3 October 2016

1 reference

Ondansetron (English)

electronic Essential Medicines List medicine ID

3 October 2016

DeCS ID

30632

0 references

0 references

1 reference

28 October 2013

1 reference

9 July 2020

Microsoft Academic ID (discontinued)

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

1 reference

1 reference